Aytu BioPharma Statistics
Share Statistics
Aytu BioPharma has 6.15M shares outstanding. The number of shares has increased by 10.45% in one year.
| Shares Outstanding | 6.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.92M |
| Failed to Deliver (FTD) Shares | 2.18K |
| FTD / Avg. Volume | 6.11% |
Short Selling Information
The latest short interest is 192.76K, so 3.13% of the outstanding shares have been sold short.
| Short Interest | 192.76K |
| Short % of Shares Out | 3.13% |
| Short % of Float | 3.25% |
| Short Ratio (days to cover) | 10.45 |
Valuation Ratios
The PE ratio is -1 and the forward PE ratio is 4.14.
| PE Ratio | -1 |
| Forward PE | 4.14 |
| PS Ratio | 0.19 |
| Forward PS | 0.1 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -11.37 |
| PEG Ratio | n/a |
Enterprise Valuation
Aytu BioPharma Inc. has an Enterprise Value (EV) of -1.28M.
| EV / Earnings | 0.08 |
| EV / Sales | -0.02 |
| EV / EBITDA | 1.26 |
| EV / EBIT | 0.24 |
| EV / FCF | 0.92 |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.55.
| Current Ratio | 0.99 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.55 |
| Total Debt / Capitalization | 35.31 |
| Cash Flow / Debt | -0.09 |
| Interest Coverage | -1.1 |
Financial Efficiency
Return on equity (ROE) is -0.57% and return on capital (ROIC) is -13.8%.
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -13.8% |
| Revenue Per Employee | 794.14K |
| Profits Per Employee | -155.33K |
| Employee Count | 102 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.09 |
Taxes
| Income Tax | 1.77M |
| Effective Tax Rate | -0.13 |
Stock Price Statistics
The stock price has increased by -33.33% in the last 52 weeks. The beta is -1.4, so Aytu BioPharma 's price volatility has been lower than the market average.
| Beta | -1.4 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 1.63 |
| 200-Day Moving Average | 2.45 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (20 Days) | 35.74K |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of 81.00M and earned -15.84M in profits. Earnings per share was -2.86.
| Revenue | 81.00M |
| Gross Profit | 54.59M |
| Operating Income | -5.25M |
| Net Income | -15.84M |
| EBITDA | -1.01M |
| EBIT | -5.25M |
| Earnings Per Share (EPS) | -2.86 |
Balance Sheet
The company has 20.01M in cash and 15.13M in debt, giving a net cash position of 4.88M.
| Cash & Cash Equivalents | 20.01M |
| Total Debt | 15.13M |
| Net Cash | 4.88M |
| Retained Earnings | -319.97M |
| Total Assets | 115.83M |
| Working Capital | -514.00K |
Cash Flow
In the last 12 months, operating cash flow was -1.39M and capital expenditures 0, giving a free cash flow of -1.39M.
| Operating Cash Flow | -1.39M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.39M |
| FCF Per Share | -0.25 |
Margins
Gross margin is 67.39%, with operating and profit margins of -6.49% and -19.56%.
| Gross Margin | 67.39% |
| Operating Margin | -6.49% |
| Pretax Margin | -17.38% |
| Profit Margin | -19.56% |
| EBITDA Margin | -1.25% |
| EBIT Margin | -6.49% |
| FCF Margin | -1.71% |
Dividends & Yields
AYTU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -172.29% |
| FCF Yield | -13.6% |
Analyst Forecast
Currently there are no analyst rating for AYTU.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 6, 2023. It was a forward split with a ratio of 20:1.
| Last Split Date | Jan 6, 2023 |
| Split Type | forward |
| Split Ratio | 20:1 |
Scores
| Altman Z-Score | -3.29 |
| Piotroski F-Score | 3 |